Gene therapy Etu-cel Shows Sustained Clinical Benefit in Wiskott-Aldrich Syndrome: NEJM
Researchers have found in a new study that treatment with etu-cel demonstrated a sustained clinical benefit in patients with Wiskott-Aldrich syndrome, supporting its potential as a therapeutic option for this rare inherited disorder.
A groundbreaking study published in The New England Journal of Medicine (NEJM) brings strong clinical validation to etuvetidigene autotemcel (etu-cel), an investigational autologous gene therapy for Wiskott–Aldrich syndrome (WAS). The integrated analysis showed a high overall survival rate of 96% at both 1-year and 5-year follow-up, alongside substantial, sustained reductions in severe infections and bleeding events.
Wiskott–Aldrich syndrome is a rare, X-linked, life-threatening primary immunodeficiency and platelet disorder caused by pathogenic variants in the WAS gene. The disorder traditionally leaves pediatric patients highly vulnerable to life-threatening infections, severe autoimmunity, bleeding complications, and hematologic malignancies.
Etuvetidigene autotemcel (etu-cel) utilizes hematopoietic stem and progenitor cells (HSPCs) harvested from the patient, transduced ex vivo with a self-inactivating lentiviral vector carrying functional WAS complementary DNA, and then reinfused back into the recipient.
Study Design and Methodology
To comprehensively evaluate the long-term safety and clinical efficacy of etu-cel, researchers pooled patient data across three prospectively tracked clinical streams:
A Phase 1–2 study (n = 8)
A Phase 3 trial (n = 10)
An expanded-access program (n = 9)
A total of 27 participants received a single intravenous infusion of etu-cel following pre-treatment with rituximab and a reduced-intensity conditioning regimen. The median age at the time of gene therapy was 2.6 years (range: 1.0 to 35.1 years). Surviving participants had a median follow-up duration of 5.7 years, extending up to 13.3 years.
In an integrated analysis of 27 patients across three clinical streams, treatment with etuvetidigene autotemcel (etu-cel) yielded a 96% overall survival rate at both 1-year and 5-year post-infusion. Over a median follow-up period of 5.7 years (extending up to 13.3 years), the therapy demonstrated substantial clinical efficacy by reducing severe infection rates by over 92% (from 2.00 to 0.15 events per person-year between 6 and 18 months) and moderate-to-severe bleeding events by 60% (from 2.00 to 0.80 events per person-year in the first year). Additionally, etu-cel maintained a favorable safety profile with no evidence of insertional oncogenesis, where the most common Grade 3 or higher adverse events were limited to central venous catheter–related infections.
The study established primary efficacy endpoints around overall survival, severe infection rates (measured between 6 to 18 months post-infusion), and moderate to severe bleeding rates during the first 12 months after gene therapy. Event rates were evaluated per person-year of observation and compared directly against each participant’s pre-treatment baseline rate.
The safety assessments delivered highly encouraging signals, particularly regarding vector safety:
No Insertional Oncogenesis: Crucially, investigators observed no evidence of insertional mutagenesis or oncogenesis—a historical limitation of early-generation gamma-retroviral gene vectors.
Adverse Events: The most frequent Grade 3 or higher adverse event reported across the cohort was central venous catheter–related infection.
Mortality: Out of 27 participants, one death was reported during the follow-up period.
Clinical Takeaway
The findings demonstrate that ex vivo lentiviral gene therapy using etu-cel offers durable, long-term therapeutic reconstitution for patients with Wiskott–Aldrich syndrome. By offering sustained disease control, significant reductions in severe clinical complications, and a favorable safety profile without vector-related oncogenesis, etu-cel represents a pivotal advancement in the curative landscape for this inherited immunodeficiency.
